Overview

Safety Study of Gene-modified Autologous Fibroblasts in Recessive Dystrophic Epidermolysis Bullosa

Status:
Completed

Trial end date:
2018-03-01

Target enrollment:

Participant gender:

Summary

Recessive dystrophic epidermolysis bullosa (RDEB) is a severe form of blistering skin disease caused by mutations in COL7A1 gene. This study aims to assess the safety of intradermal injections of gene-modified autologous fibroblasts in 5-10 adults with RDEB.

Phase:

Phase 1

Details

Lead Sponsor:

King's College London

Collaborator:

University College, London